Demographics of patients with ITP and non-ITP thrombocytopenia syndromes
| . | ITP . | Non-ITP . | ||
|---|---|---|---|---|
| . | Definite ITP subgroup . | Possible ITP subgroup . | Total . | n= 339 . |
| (n = 104) . | (n = 398) . | (n = 502) . | ||
| Age at enrollment, y; median (IQR) | 52.5 (34.8, 67.0) | 55.0 (36.0, 68.8) | 54.5 (36.0, 68.0) | 54.0 (37.0, 67.0) |
| Female, n (%) | 64 (61.5) | 231 (58.0) | 295 (58.8) | 172 (50.7) |
| Received previous ITP treatment, n (%) | 104 (100.0) | 271 (68.1) | 375 (74.7) | 75 (22.1) |
| Follow-up, y; median (IQR) | 9.8 (5.3, 13.0) | 4.2 (1.5, 10.1) | 5.6 (1.9, 11.1) | 3.7 (1.3, 8.4) |
| Nadir platelet count (median, IQR) ×109/L | 3 (1, 10) | 23 (5, 58) | 16 (3, 46) | 78 (44, 113) |
| Platelets <20 × 109/L ever, n (%) | 62 (59.6) | 148 (37.2) | 210 (41.8) | 25 (7.4) |
| Number of platelet count measures per patient | 54.0 (30.0, 85.3) | 12.0 (5.0, 28.8) | 17.0 (7.0, 41.8) | 8.0 (4.0, 21.0) |
| . | ITP . | Non-ITP . | ||
|---|---|---|---|---|
| . | Definite ITP subgroup . | Possible ITP subgroup . | Total . | n= 339 . |
| (n = 104) . | (n = 398) . | (n = 502) . | ||
| Age at enrollment, y; median (IQR) | 52.5 (34.8, 67.0) | 55.0 (36.0, 68.8) | 54.5 (36.0, 68.0) | 54.0 (37.0, 67.0) |
| Female, n (%) | 64 (61.5) | 231 (58.0) | 295 (58.8) | 172 (50.7) |
| Received previous ITP treatment, n (%) | 104 (100.0) | 271 (68.1) | 375 (74.7) | 75 (22.1) |
| Follow-up, y; median (IQR) | 9.8 (5.3, 13.0) | 4.2 (1.5, 10.1) | 5.6 (1.9, 11.1) | 3.7 (1.3, 8.4) |
| Nadir platelet count (median, IQR) ×109/L | 3 (1, 10) | 23 (5, 58) | 16 (3, 46) | 78 (44, 113) |
| Platelets <20 × 109/L ever, n (%) | 62 (59.6) | 148 (37.2) | 210 (41.8) | 25 (7.4) |
| Number of platelet count measures per patient | 54.0 (30.0, 85.3) | 12.0 (5.0, 28.8) | 17.0 (7.0, 41.8) | 8.0 (4.0, 21.0) |
Definite ITP was defined as patients with ITP who had a documented response to intravenous immune globulin, prednisone, or dexamethasone. A treatment response was defined as doubling of the baseline platelet count and having at least 1 measure of platelet counts above 50 × 109/L within 4 weeks after treatment.